Montreal, Canada -- February 4,
2021 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc. (OTC
PINK:
"SBFM"), a pharmaceutical company focused on the research,
development and commercialization of oncology and antiviral
drugs today
announced that it has signed an exclusive license
agreement with the University of Georgia ("UGA") for two
Anti-Coronavirus compounds which UGA had previously developed and
patented. Sunshine Biopharma and UGA will advance the development
of these two compounds in parallel with Sunshine Biopharma's own
SBFM-PL4. The next step in the development plan involves testing of the
efficacy of these compounds in transgenic mice. Mice which have been
genetically engineered to become susceptible to infection
by
SARS-CoV-2, the
causative agent of COVID-19, will be challenged with the virus and
subsequently treated with the test compounds to
determine if
progression to diseases can be arrested. Such studies are anticipated
to be underway later this month.
"We are delighted to have
reached this agreement with the University of Georgia," said Dr.
Steve N. Slilaty, CEO of Sunshine Biopharma. "UGA's compounds
expand our war chest and enhance our effort to hone in on a most
effective treatment for COVID-19," he added.
About
Sunshine Biopharma's COVID-19
Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of COVID-19, the current
ongoing pandemic that has claimed the lives of over
2.2
million people
worldwide since it first appeared in December 2019. There are
currently no drugs that can effectively arrest replication of the
virus in people who have contracted the illness. On May 22, 2020,
Sunshine Biopharma filed a provisional patent application for a
library of molecules which were designed to inhibit the Coronavirus
proteases, thus shutting down the ability of the virus to multiply
and cause illness. Sunshine Biopharma has since screened the
library and identified a lead Anti-Coronavirus compound (SBFM-PL4).
The Company is currently conducting a series of in
vitro tests to
evaluate its specific inhibitory activity of SBFM-PL4 against the
SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus
encoded proteases essential for viral replication. Following the
initial in
vitro studies,
SBFM-PL4 will be moved forward to the cell culture testing stage
and assessment in Coronavirus infected mice before entering human
clinical trials.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property
pertaining to Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma
Inc.
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com